Duke Cancer Institute
17
2
2
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
17.6%
3 terminated/withdrawn out of 17 trials
78.6%
-7.9% vs industry average
0%
0 trials in Phase 3/4
36%
4 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Role: collaborator
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Role: collaborator
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Role: collaborator
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Role: collaborator
Mindfulness Meditation in Glioma Patients
Role: collaborator
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
Role: collaborator
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Role: collaborator
Endometrial Cancer Diet and Exercise
Role: collaborator
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
Role: collaborator
Early Palliative Care Intervention in Malignant Glioma
Role: collaborator
Nivolumab With DC Vaccines for Recurrent Brain Tumors
Role: collaborator
Four Conversations RCT
Role: collaborator
Using a Geriatric Oncology Assessment to Link With Services
Role: collaborator
Feasibility and Smokers' Reactions to DNA Feedback
Role: collaborator
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Role: collaborator
Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention
Role: collaborator
Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer
Role: lead
All 17 trials loaded